Abnormal pontine activation in pathological laughing as shown by functional magnetic resonance imaging

To explore the aetiology of pathological laughing, a 65-year-old woman with pathological laughing was examined by 3-T functional magnetic resonance imaging (fMRI) before and after treatment with drugs. Here, we report that the patient consistently showed exaggerated pontine activation during the performance of three tasks before treatment, whereas abnormal pontine activation was no longer found after successful treatment with the selective serotonin reuptake inhibitor, paroxetine. Our findings in this first fMRI study of pathological laughing suggest that serotonergic replacement decreases the aberrant activity in a circuit that involves the pons

書札礼と文書から見た室町・戦国期の儀礼秩序

2007-03-31departmental bulletin pape

The Study of Analog to Digital Converter

Comparing the cases in which the analog quantity and digital one were respectively applied the latter case i.e. the digital system has the following satisfactory merits; 1. can describe narrowly in the value of quantity. 2. higher ordered precision in the transportation. 3. a wid application can be obtained beam of the numbers, being common to all quantities. 4. can deal with acomplicated case applying the digital system. Hence, the author studied the analog to digital converter, especially digital voltage in device.departmental bulletin pape

銀塩添加による水素吸蔵合金電極のサイクル特性の改善

Articledepartmental bulletin pape

Supplementary Data 3 from Serum Autoantibody Signature of Ductal Carcinoma <i>In Situ</i> Progression to Invasive Breast Cancer

PDF file - 112K</p

Supplementary Data 2 from Serum Autoantibody Signature of Ductal Carcinoma <i>In Situ</i> Progression to Invasive Breast Cancer

PDF file - 93K</p

Supplementary Data 4 from Serum Autoantibody Signature of Ductal Carcinoma <i>In Situ</i> Progression to Invasive Breast Cancer

PDF file - 71K</p

Supplementary Data 1 from Serum Autoantibody Signature of Ductal Carcinoma <i>In Situ</i> Progression to Invasive Breast Cancer

PDF file - 303K</p

Supplementary Data from Identification of a New Panel of Serum Autoantibodies Associated with the Presence of <i>In situ</i> Carcinoma of the Breast in Younger Women

Supplementary Data from Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Wome

Data_Sheet_1_Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer.docx

ZNF217 is a candidate oncogene with a wide variety of deleterious functions in breast cancer. Here, we aimed at investigating in a pilot prospective study the association between ZNF217 mRNA expression levels and the clinical response to neoadjuvant endocrine therapy (ET) in postmenopausal ER-positive (ER+) breast cancer patients. Core surgical biopsy samples before treatment initiation and post-treatment were obtained from 68 patients, and Ki-67 values measured by immunohistochemistry (IHC) were used to identify responders (n = 59) and non-responders (n = 9) after 4 months of ET. We report for the first time that high ZNF217 mRNA expression level measured by RT-qPCR in the initial tumor samples (pre-treatment) is associated with poor response to neoadjuvant ET. Indeed, the clinical positive response rate in patients with low ZNF217 expression levels was significantly higher than that in those with high ZNF217 expression levels (P = 0.027). Additionally, a retrospective analysis evaluating ZNF217 expression levels in primary breast tumor of ER+/HER2-/LN0 breast cancer patients treated with adjuvant ET enabled the identification of poorer responders prone to earlier relapse (P = 0.013), while ZNF217 did not retain any prognostic value in the ER+/HER2-/LN0 breast cancer patients who did not receive any treatment. Altogether, these data suggest that ZNF217 expression might be predictive of clinical response to ET.</p